Discovery to design to delivery: how patients are helping us innovate

Vanco Vlastimil (金禾娱乐城 S.A.) — Wed, 05 Apr 2023 09:44:16 +0000

Kate Trenam, Early Patient Engagement

Vanco Vlastimi鈥� Wed 05/04/2023 - 11:44

Discovering and developing new medicines is a key part of what we do here at 金禾娱乐城. But we believe that a new medicine is only truly valuable and innovative if it鈥檚 meaningful to patients. It has to be a solution that patients really want, and which makes a genuine difference to their lives.

The creation of meaningful medicines at 金禾娱乐城 doesn鈥檛 happen by luck or by chance, it happens because we work hard to implement partnerships with patients at all stages of the drug development process.

There is growing evidence that patients鈥� contributions during the very early stages of drug development can have a positive impact on research into new drugs. Because at this stage researchers are gaining an understanding of patient communities and their unmet needs, patient-friendly research approaches and identifying meaningful outcome measures for patients. Who better to inform these processes than the patients themselves?

At 金禾娱乐城 we have developed a new end-to-end framework designed to ensure that patients and key stakeholders can provide input as early as possible into our research and development programs, as well as the entire drug lifecycle. At the clinical trial stage, we co-create protocols with patients / patient advocacy groups to help us assess protocol complexity and minimize the burden on patients.

Today, approximately 46% of our trials also have a Decentralized Clinical Trials (DCT) patient-centric component. DCTs help to make our clinical trials more accessible and easier to participate in for patients who may not be able to easily access a clinical trial in person, and they can help us to reach patients living in under-represented geographies.

In the area of Parkinson鈥檚, we have joined forces with Parkinson鈥檚 UK, and the Parkinson's Foundation in the U.S., to establish a Patient Engagement Council for Parkinson鈥檚 Research (PECPR). The aim of the council is to ensure that patient insights are central to the overall strategy and activities across 金禾娱乐城鈥檚 Parkinson鈥檚 Disease research and early clinical development program. Through this collaborative partnership, the council aims to embed patient involvement in the earliest stages and throughout each step of 金禾娱乐城鈥檚 Parkinson鈥檚 drug development program.

At 金禾娱乐城 we celebrate the fact that patients are increasingly active and empowered when it comes to decisions about their healthcare 鈥� they are no longer 鈥榗ustomers鈥�, but more 鈥榗o-creators鈥� in the R&D process. We celebrate it because we hope that by closing the gap between scientists and patients, we can discover new ways to target the drivers of disease.

To learn more about how innovation drives everything we do visit Innovation is | 金禾娱乐城

innovation

322 Likes

Patient engagement

Discovery to design to delivery: how patients are helping us innovate

Leave a Comment